
|Slideshows|May 31, 2018
New FDA Warning
Author(s)James Phelps, MD
A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
Home-Based tDCS for Depression: Expanding Access to Neuromodulation Treatment
2
FDA Approves Tauklarify (MK-6240) For Tau Pathology Detection in Alzheimer Disease
3
HLP003, Deuterated Psilocin, as an Adjunctive Therapy for Major Depressive Disorder
4
Morning Rounds: News From August 10-16
5









